NIT
IOVA icon

NumerixS Investment Technologies’s Iovance Biotherapeutics IOVA Stock Holding History

NumerixS Investment Technologies’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,900
Closed -$217K – 416
2020
Q2 		$217K Buy
+7,900
New +$260K 0.06% 357

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NumerixS Investment Technologies's IOVA Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of Iovance Biotherapeutics (IOVA) in Q3 2020, closing a stake of 7,900 shares — an estimated $217K sold.

NumerixS Investment Technologies first reported a position in IOVA in Q2 2020 and held it in 1 quarter. The position peaked at $217K in Q2 2020. 252 funds tracked by Wall St. Rank hold IOVA as of Q3 2020.

  • NumerixS Investment Technologies reported no remaining Iovance Biotherapeutics position as of Q3 2020 after selling out during the quarter.
  • NumerixS Investment Technologies sold 7,900 Iovance Biotherapeutics shares in Q3 2020, an estimated $217K.
  • NumerixS Investment Technologies first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 1 quarter.
  • NumerixS Investment Technologies's Iovance Biotherapeutics position peaked at $217K in Q2 2020.
  • 252 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.